Landmark Longitudinal Prostate Cancer Study Released
A new study confirms Cleveland Diagnostics’ IsoPSA test effectively differentiates between low- and high-risk prostate cancer patients.
A new study confirms Cleveland Diagnostics’ IsoPSA test effectively differentiates between low- and high-risk prostate cancer patients.
LabGenomics USA acquired Integrated Molecular Diagnostics labs and now operates four CLIA-certified diagnostic labs in the U.S.
Key Proteo has initiated plans to build a new CLIA-certified laboratory as part of its growth strategy to enhance newborn screening programs.Â
Daxor Corporation has announced expansion of blood volume analysis (BVA) into five of six hospitals in the Southeast.
Read MoreSimple HealthKit has teamed up with Walmart to make Simple HealthKit’s at-home diabetes, respiratory and sexual wellness tests available.
Read MoreVerichem now offers customers free access to the its web-based and online calibration verification data reduction and test reporting programs.
Read MoreThe inFoods IBS test has been validated for use with finger stick blood samples simplifying collection and facilitating access to the test.
Read MoreMost current molecular tests have been developed as laboratory-developed tests, outside the strict regulatory framework of the FDA.
Read MoreVerichem Labs now offers a range of multi-level liquid stable biosynthetic clinical reference materials for use with urine chemistry assays.Â
Read MoreSEngine has been certified through the NY State Department of Health’s CLEP program to perform the PARIS Test on samples from the state.
Read MorePrecision Health Solutions launched a new at-home testing service that brings clinical diagnostic testing to the patient’s home.
Read MoreRegulations and guidelines sometimes make it difficult to perform linearity testing and calibration verification in a useful way.Â
Read MoreRapid Novor obtained the CLIA certification for its EasyM assay for Multiple Myeloma as a laboratory developed test.
Read MoreVisby Medical has received 510(k) clearance and was granted a CLIA waiver from the FDA for its second-generation POC sexual health test.
Read MoreVeracyte CEO Marc Stapley outlines how single-cancer testing is giving pathologists, clinicians, and patients an edge.
Read MoreProterixBio’s ST2 Assay is for use in conjunction with clinical evaluation in assessing the prognosis of patients with chronic heart failure.Â
Read MoreArima Genomics announced an agreement with Protean BioDiagnostics to make its next-generation sequencing-based test available to clinicians.
Read MoreThe Association of Medical Pathology (AMP) applauded Congress for not including the VALID Act in the Consolidated Appropriations Act of 2023.
Read More